This invention provides a series of new oxindole derivatives 1-21, evaluated for their antiglycation potential by using in vitro BSA-MG glycation model. These derivatives showed a varying degree of antiglycation activity with IC
50
values ranging between 150-856 μM. Compound 14 (IC
50
=150.4±2.5 μM) was found to be the most potent among all derivatives, even better than the standard inhibitor i.e. rutin (IC
50
=294.5±1.50 followed by compounds 13 and 8 with IC
50
value of 194.40±2.5 and 211.41±4.1 μM, respectively.
Oxindole Derivatives: Synthesis and Antiglycation Activity
Oxindole derivatives 3-25 have been synthesized from commercially available oxindole by refluxing with different
aromatic aldehydes in good yields. Their in vitro antiglycation potential has been evaluated. They showed a varying
degree of antiglycation activity with IC50 values ranging between 150.4 - 856.7 µM. 3-[(3-Chlorophenyl)methylidene]-
1,3-dihydro-2H-indol-2-one (IC50 = 150.4 ± 2.5 µM) is the most active compound among the series, better than the standard
rutin with an IC50 value 294.5 ± 1.50 µM. The structures of the compounds were elucidated by 1H-NMR and mass
spectroscopy and elemental analysis. A limited structure-activity relationship has been developed.